Eli Lilly Reports Phase 3 TRANSCEND-T2D-2 Results, With Retatrutide Achieving Greater A1C Reduction And Weight Loss Than Ozempic In Adults With Type 2 Diabetes

Loading news article.

Eli Lilly Reports Phase 3 TRANSCEND-T2D-2 Results, With Retatrutide Achieving Greater A1C Reduction And Weight Loss Than Ozempic In Adults With Type 2 Diabetes | WAPE

Eli Lilly Reports Phase 3 TRANSCEND-T2D-2 Results, With Retatrutide Achieving Greater A1C Reduction And Weight Loss Than Ozempic In Adults With Type 2 Diabetes

Article summary

Related companies

Comments —